Clinical spectrum of leishmaniasis

Clinical Infectious Diseases

Volumn 22, Issue 1, 1996, Pages 1-13

  Pearson, Richard D ^a   De Queiroz Sousa, Anastacio ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CHLORPHENOTANE; DIETHYLTOLUAMIDE; MEGLUMINE ANTIMONATE; PENTAMIDINE ISETHIONATE; RECOMBINANT GAMMA INTERFERON; STIBOGLUCONATE SODIUM;

ANEMIA; ARTHRALGIA; CARDIOTOXICITY; CELLULAR IMMUNITY; HEADACHE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; LEISHMANIA; MALAISE; MYALGIA; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; VOMITING;

EID: 0030051907     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.1.1     Document Type: Review

References (49)

1. Lainson R, Shaw JJ. Evolution, classification and geographic distribution. In: Peters W, Killick-Kendrick R, eds. The Leishmaniases in biology and medicine. Vol 1. London: Academic Press, 1987:1-120.
2. Pearson RD, De Queiroz Sousa, A. Leishmania species: visceral (kalaazar), cutaneous, and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingston, 1994:2428-42.
3. Division of Communicable Disease Prevention and Control, Communicable Disease Program, HPC/HCT, PAHO. Leishmaniasis in the Americas. Epidemiol Bull 1994;15:8-11.
4. Addy M, Nandy A. Ten years of kala-azar in West Bengal. Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ 1992;70:341-6.
5. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 1994;51:826-36.
6. Jeronimo SMB, Oliveira RM, Mackay S, et al. An urban outbreak of visceral leishmaniasis in Natal, Brazil. Trans R Soc Trop Med Hyg 1994;88:386-8.
7. Montalban C, Calleja JL, Erice A, et al. Visceral leishmaniasis in patients with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect 1990;21:261-70.
8. Rosenthal E, Marty P, Poizot-Martin I, et al. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 1995;89:159-62.
9. Moulin B, Ollier J, Bouchouareb D, Purgus R, Olmer M. Leishmaniasis: a rare cause of unexplained fever in a renal graft recipient. Nephron 1992;60:360-2.
10. Magill AJ, Grogl M, Gasser RA, Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993;328:1383-7.
11. Theodos CM, Ribeiro JM, Titus RG. Analysis of enhancing effect of sand fly saliva on Leishmania infection in mice. Infect Immun 1991; 59:1592-8.
12. Wilson ME, Donnelson JE, Pearson RD, Ramamoorthy R. Macrophage receptors and leishmania. In: Korkonen TK, Hovi T, Makela PH, eds. Molecular recognition in host-parasite interactions. New York: Plenum Publishing, 1992:17-30.
13. Evans TG, Teixeira MJ, McAulife IT, et al. Epidemiology of visceral leishmaniasis in northeast Brazil. J Infect Dis 1992;166:1124-32.
14. Desjeux P. Information on the epidemiology and control of the leishmaniasis by country and territory. WHO/Leish/91.30. Geneva: World Health Organization, 1991.
15. Grimaldi G Jr, Tesh RB, McMahon-Pratt DM. A review of the geographic distribution and epidemiology of leishmaniasis in the new world. Am J Trop Med Hyg 1989;41:687-725.
16. Shaw PK, Quigg LT, Allain DS, Juranek DD, Healy GR. Autochthonous dermal leishmaniasis in Texas. Am J Trop Med Hyg 1976;25:788-96.
17. Gustafson TL, Reed CM, McGreevy PB, Pappas MG, Fox JC, Lawyer PG. Human cutaneous leishmaniasis acquired in Texas. Am J Trop Med Hyg 1985;34:58-63.
18. Locksley RM, Louis JA. Immunology of leishmaniasis. Curr Opin Immunol 1992;4:413-8.
19. Scharton-Kersten T, Scott P. The role of the innate immune response in ThI cell development following Leishmania major infection. J Leukoc Biol 1995;57:515-22.
20. + subsets in leishmaniasis. J Cell Biochem 1993;53:323-8.
21. Plant JE, Blackwell JM, O'Brien AD, Bradley DJ, Glynn AA. Are the Lsh and Ity disease resistance genes at one locus on mouse chromosome 1? Nature 1982;297:510-1.
22. Formica S, Roach TI, Blackwell JM. Interaction with extracellular matrix proteins influences Lsh/Ity/Bcg (candidate Nramp) gene regulation of macrophage priming/activation for tumour necrosis factor-alpha and nitrite release. Immunology 1994;82:42-50.
23. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating cytokine. J Clin Invest 1983;72:1506-10.
24. + T lymphocyte plasma membrane. J Exp Med 1991;174:755-9.
25. Green SJ, Meltzer MS, Hibbs JB Jr, Nacy CA. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 1990;144:1278-85.
26. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin-12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
27. Holaday BJ, Pompeu MML, Jeronimo S, et al. Potential role for interleukin-10 in the immunosuppression associated with kala-azar. J Clin Invest 1993;92:2626-32.
28. Barral-Netto M, Barrai A, Brownell CE, et al. Transforming growth factor-beta in leishmanial infections: a parasite escape mechanism. Science 1992;247:545-8.
29. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986;154:1003-11.
30. Barral A, Barral-Netto M, Almeida R, et al. Lymphadenopathy associated with Leishmania braziliensis cutaneous infections. Am J Trop Med Hyg 1992;47:587-92.
31. Pearson RD, Wheeler DA, Harrison LH, Kay HD. The immunobiology of leishmaniasis. Rev Infect Dis 1983;5:907-27.
32. Chulay JD, Bryceson ADM. Quantitation of amastigotes of Leishmania donovani in smears of patients with visceral leishmaniasis. Am J Trop Med Hyg 1983;32:475-9.
33. Pearson RD, Navin TR, Sousa A de Q, Evans TG. Leishmaniasis. In: Kass EH, Platt R, eds. Current therapy in infectious diseases. Vol 3. Toronto: BC Decker, 1990:384-9.
34. Rodriguez N, Guzman B, Rodas A, Takiff H, Bloom BR, Convit J. Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hybridization. J Clin Microbiol 1994;32:2246-52.
35. Nuzum E, White F III, Thakur C, et al. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood. J Infect Dis 1995;171:751-4.
36. Grogl M, Thomason TN, Franke ED. Drug resistance in leishmaniasis: its implications in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 1992;47:117-26.
37. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
38. Gasser RA Jr, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994;18:83-90.
39. Thakur CP, Sinha GP, Pandey AK, Barat D, Singh RK. Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison. Bull World Health Organ 1994;72:931-6.
40. Torre-Cisneros J, Villanueva JL, Kindelan JM, Jurado R, Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis 1993;17:625-7.
41. Badaro R, Johnson WD Jr. The role of interferon-γ in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 1993;167(suppl 1):S13-7.
42. El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major. A double-blind control study. J Am Acad Dermatol 1992;27:227-31.
43. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimoniate (glucan-time) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990;42:43-50.
44. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconzole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992;165:528-34.
45. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992;326:741-4.
46. Herwaldt BL, Neva FA, Herman JD. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992;327:498-9.
47. Convit J, Castellanos PL, Ulrich M, et al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J Infect Dis 1989;160:104-15.
48. Tesh RB. Control of zoonotic visceral leishmaniasis: is it time to change strategies? Am J Trop Med Hyg 1995;52:287-92.
49. Greenblatt CL. The present and future of vaccination for cutaneous leishmaniasis. In: Mizrahi A, Hertman I, Klingberg MA, et al., eds. Progress in clinical and biological research. Vol 47. New developments with human and veterinary vaccines. New York: Alan R Liss, 1980:259-85.